NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Lack of association between acyclovir use and survival in an observational cohort enrolled by the community program for clinical research on AIDS (CPCRA).

Torres R, Neaton J, Wentworth D, Barr M, Abrams D, Sherer R, Ward T, Sampson J; Conference on Retroviruses and Opportunistic Infections.

Program Abstr 3rd Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 3rd 1996 Wash D C. 1996 Jan 28-Feb 1; 3rd: 121.

Clinical Directors Network, Inc. N.Y., N.Y.

Objective: To evaluate the effect of acyclovir use on survival in HIV seropositive persons enrolled in an observational study by 17 units conducting community-based clinical trials in the United States. Design: Analyses were conducted on 2,368 HIV seropositive persons enrolled 9/90-11/92 visit and followed through 7/94 with CD4+ T-cell counts less than 500/mm 3 who had complete baseline data and attended at least one follow-up visit. Results: 345 (14.5%) reported acyclovir use, and 70.5% reported antiretroviral drug use at baseline. Those using acyclovir at baseline had more advanced HIV disease than those not using acyclovir (mean CD4+ count 148 and 202 cells/mm 3 , respectively) and were more likely to be white, male and gay and have a history of herpes simplex or zoster. A Cox regression analysis found that use of acyclovir at baseline was associated with a non-significant 18% increased risk of death p=.21). Intermittent use of acyclovir was associated with a 48% increased risk of death (p=.004); continuous acyclovir use was not associated with mortality (RR=l.13; p=.38); and "ever" use of acyclovir was associated with a 33% increased risk of death (p=.0004). Use of acyclovir varied markedly by unit, and risk of death varied significantly among 4 groups of units ranked by acyclovir use (P=.04). The unit with the highest acyclovir use (45.5910) had a lower risk of death than the group of units with the lowest use (3.2%), (RR=0.73; P=.03). Conclusion: Use of acyclovir was not associated with improved survival in this large cohort of 2,368 HIV-infected patients, and our findings suggest that intermittent use of acyclovir may be associated with an increased risk of death. Selection biases could have a marked effect on these findings as well as findings from other observational studies.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Acyclovir
  • Biomedical Research
  • CD4 Lymphocyte Count
  • HIV Infections
  • HIV Seropositivity
  • Herpes Simplex
  • Herpes Zoster
  • Humans
  • Male
  • Survival
  • United States
  • epidemiology
  • mortality
Other ID:
  • 96920367
UI: 102216418

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov